BACKGROUND: Next-generation sequencing was performed on pulmonary and pancreatic fine-needle aspirations (FNAs) and on paired FNAs and resected primary tumors from the same patient. METHODS: DNA was isolated in formalin-fixed, paraffin-embedded cell blocks from 16 pulmonary FNAs, 23 pancreatic FNAs, and 5 resected pancreatic primary tumors. Next-generation sequencing was performed for 4561 exons of 287 cancer-related genes and for 47 introns of 19 genes on indexed, adaptor-ligated, hybridization-captured libraries using a proprietary sequencing system (the Illumina HiSeq 2000). RESULTS: Genomic profiles were generated successfully from 16 of 16 (100%) pulmonary FNAs, which included 14 nonsmall cell lung cancers (NSCLCs) and 2 small cell lung cancers (SCLCs). The NSCLC group included 6 adenocarcinomas, 5 squamous cell carcinomas, and 3 NSCLCs not otherwise specified. Genomic profiles were successfully obtained from 23 of 23 (100%) pancreatic FNAs and from 5 of 5 (100%) matched pancreatic primary tumors, which included 17 ductal adenocarcinomas, 3 mucinous adenocarcinomas, 2 adenocarcinomas NOS, and 1 neuroendocrine tumor. Eighty-one genomic alterations were identified in the 16 pulmonary FNAs (average, 5.1 genomic alterations per patient); and the most common genomic alterations were TP53, RB1, SOX2, PIK3CA, and KRAS. Eighty-seven genomic alterations were identified in the 23 pancreatic tumor FNAs (average, 3.8 genomic alterations per patient); and the most common genomic alterations were KRAS, TP53, CDKN2A/B, SMAD4, and PTEN. Among the pancreatic tumors, there was 100% concordance of 20 genomic alterations that were identified in 5 patient-matched FNA and surgical primary tumor pairs. CONCLUSIONS: The authors were able to perform next-generation sequencing reliably on FNAs of pulmonary and pancreatic tumors, and the genomic alterations discovered correlated well with those identified in matched resected pancreatic tumors.
BACKGROUND: Next-generation sequencing was performed on pulmonary and pancreatic fine-needle aspirations (FNAs) and on paired FNAs and resected primary tumors from the same patient. METHODS: DNA was isolated in formalin-fixed, paraffin-embedded cell blocks from 16 pulmonary FNAs, 23 pancreatic FNAs, and 5 resected pancreatic primary tumors. Next-generation sequencing was performed for 4561 exons of 287 cancer-related genes and for 47 introns of 19 genes on indexed, adaptor-ligated, hybridization-captured libraries using a proprietary sequencing system (the Illumina HiSeq 2000). RESULTS: Genomic profiles were generated successfully from 16 of 16 (100%) pulmonary FNAs, which included 14 nonsmall cell lung cancers (NSCLCs) and 2 small cell lung cancers (SCLCs). The NSCLC group included 6 adenocarcinomas, 5 squamous cell carcinomas, and 3 NSCLCs not otherwise specified. Genomic profiles were successfully obtained from 23 of 23 (100%) pancreatic FNAs and from 5 of 5 (100%) matched pancreatic primary tumors, which included 17 ductal adenocarcinomas, 3 mucinous adenocarcinomas, 2 adenocarcinomas NOS, and 1 neuroendocrine tumor. Eighty-one genomic alterations were identified in the 16 pulmonary FNAs (average, 5.1 genomic alterations per patient); and the most common genomic alterations were TP53, RB1, SOX2, PIK3CA, and KRAS. Eighty-seven genomic alterations were identified in the 23 pancreatic tumor FNAs (average, 3.8 genomic alterations per patient); and the most common genomic alterations were KRAS, TP53, CDKN2A/B, SMAD4, and PTEN. Among the pancreatic tumors, there was 100% concordance of 20 genomic alterations that were identified in 5 patient-matched FNA and surgical primary tumor pairs. CONCLUSIONS: The authors were able to perform next-generation sequencing reliably on FNAs of pulmonary and pancreatic tumors, and the genomic alterations discovered correlated well with those identified in matched resected pancreatic tumors.
Authors: Alda L Tam; Howard J Lim; Ignacio I Wistuba; Anobel Tamrazi; Michael D Kuo; Etay Ziv; Stephen Wong; Albert J Shih; Robert J Webster; Gregory S Fischer; Sunitha Nagrath; Suzanne E Davis; Sarah B White; Kamran Ahrar Journal: J Vasc Interv Radiol Date: 2015-11-25 Impact factor: 3.464
Authors: Simon R Turner; Darren Buonocore; Patrice Desmeules; Natasha Rekhtman; Snjezana Dogan; Oscar Lin; Maria E Arcila; David R Jones; James Huang Journal: Lung Cancer Date: 2018-03-07 Impact factor: 5.705
Authors: Alexander Drilon; Lu Wang; Maria E Arcila; Sohail Balasubramanian; Joel R Greenbowe; Jeffrey S Ross; Phil Stephens; Doron Lipson; Vincent A Miller; Mark G Kris; Marc Ladanyi; Naiyer A Rizvi Journal: Clin Cancer Res Date: 2015-01-07 Impact factor: 12.531
Authors: Nicole M Iñiguez-Ariza; Sina Jasim; Mabel M Ryder; Ashish V Chintakuntlawar; John C Morris; Crystal R Hilger; Michael E Menefee; Robert C Smallridge; Nina J Karlin; Constanza Alcaino; Keith C Bible Journal: J Clin Endocrinol Metab Date: 2020-07-01 Impact factor: 5.958
Authors: James H Suh; Adrienne Johnson; Lee Albacker; Kai Wang; Juliann Chmielecki; Garrett Frampton; Laurie Gay; Julia A Elvin; Jo-Anne Vergilio; Siraj Ali; Vincent A Miller; Philip J Stephens; Jeffrey S Ross Journal: Oncologist Date: 2016-05-05
Authors: Vicente Valero; Tyler J Saunders; Jin He; Matthew J Weiss; John L Cameron; Avani Dholakia; Aaron T Wild; Eun Ji Shin; Mouen A Khashab; Anne Marie O'Broin-Lennon; Syed Z Ali; Daniel Laheru; Ralph H Hruban; Christine A Iacobuzio-Donahue; Joseph M Herman; Christopher L Wolfgang Journal: Ann Surg Date: 2016-01 Impact factor: 12.969
Authors: Lester J Layfield; Sinchita Roy-Chowdhuri; Zubair Baloch; Hormoz Ehya; Kim Geisinger; Susan J Hsiao; Oscar Lin; Neal I Lindeman; Michael Roh; Fernando Schmitt; Nikoletta Sidiropoulos; Paul A VanderLaan Journal: Diagn Cytopathol Date: 2016-08-26 Impact factor: 1.582